[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
10-Jan-2008

[ | E-mail ] Share Share

Contact: Michael Stewart
michael.stewart@gabbe.com
212-220-4444
InHealth: The Institute for Health Technology Studies

Stanford researchers publish review of US medical device regulation

Report illuminates approval pathways impacting safety; innovation

WASHINGTON, D.C. - Researchers at the Stanford University Program in Biodesign have released a review of the background, mission and statutory requirements of medical device regulation in the United States. The report, published in the December 2007 issue of the Journal of Medical Devices, highlights the differences between regulations guiding medical devices versus pharmaceuticals and underscores the complexity of the approval process and post-market surveillance administered by the Food and Drug Administration (FDA).

According to the researchers, regulation plays a key role in the design, development and commercialization of new medical technologies, making a comprehensive understanding of the various regulatory requirements and their practical implementation a cornerstone of successful medical device innovation. The major barriers to moving innovative technologies from the bench to the bedside in the safest and most efficient way stem from the lack of precise scientifically based data about testing, regulatory approval and health-economic evaluation processes.

The review is part of an ongoing project at Stanford to examine how medical technology is brought to market, approved for use and subsequently enhanced over time. A key goal of the research is to build a model specific to medical technology that will be of value to current and future government initiatives aimed at enhancing the efficiency and efficacy of the regulatory process for public benefit.

"Over the last couple of years, highly publicized recalls of medical devices - such as defibrillators and pacemakers - have sparked internal debate within the FDA about ways to improve post-market surveillance and adverse event reporting," said Jan B. Pietzsch, Ph.D., Consulting Assistant Professor in the Department of Management Science and Engineering at Stanford, and lead author of the report. "By thoroughly mapping the current regulatory process, we can contribute to understanding the entire complex process of medical device innovation and how it can be improved for manufacturers, and more importantly, for patients."

The FDA's Center for Devices and Radiological Health (CDRH) is currently taking steps to improve the post-market surveillance, researchers note, including strengthening the condition of approval studies; improving medical device reporting; focusing on risk-based inspections; implementing third-party inspections; communicating risk/benefit information; and refining the FDA's communications strategy.

Distinction from Drug Regulation

In contrast to pharmaceuticals, medical devices are evaluated using a risk-based classification system that determines its regulatory pathway. Devices are placed into one of three classes: Class I devices, representing low-risk items such as examination gloves do not require performance standards; medium and high-risk devices (Classes II and III) such as infusion pumps and defibrillators follow specific regulatory requirements that vary substantially.

By using a risk-based system, said researchers, the FDA recognizes that some degree of risk is inherent in the development of devices, and further, that all hazards cannot be eliminated. There is often little or no prior experience on which to base judgments about safety and effectiveness; devices undergo performance improvement modifications during clinical trials; and results depend on the skill of the user.

Other key points from the review include:

###

The research team also includes John H. Linehan, Ph.D., Consulting Professor of Bioengineering in the Program in Biodesign and the Department of Bioengineering at Stanford; Elisabeth Paté-Cornell, Ph.D., the Burt and Deedee McMurtry Professor of Engineering and Professor and Chair of the Department of Management Science and Engineering at Stanford; and Biodesign Director Paul Yock, M.D., the Martha Meier Weiland Professor of Medicine and Bioengineering, with courtesy appointments in the Graduate School of Business and the Mechanical Engineering Department.

The study is supported by an unrestricted grant from The Institute for Health Technology Studies (InHealth), a Washington, D.C. nonprofit organization that supports research and analysis of the economic, social, and health effects of patient access to medical technology innovation.

About Stanford BioDesign

The Biodesign Program at Stanford is dedicated to training tomorrow's leaders in medical technology using an experiential approach to technology innovation. The focus of the Biodesign Program is to train the next generation of medical technology innovators, taking advantage of the wealth of experience of Biodesign faculty and affiliated industry advisors. Biodesign has established curriculum and teaching methods that provide innovation tools to engineers, physicians and business people, allowing them to create and develop innovative healthcare solutions.

About InHealth (www.inhealth.org)

Launched in 2004, The Institute for Health Technology Studies (InHealth) is a 501(c) 3 nonprofit organization that researches the social and economic impact of medical technology. InHealth is funded by unrestricted philanthropic gifts and funds research grants and educational forums. It adheres to the International Committee of Medical Journal Editors' principles of sponsorship.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.